209 related articles for article (PubMed ID: 18809675)
1. Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice.
Stoddart CA; Nault G; Galkina SA; Thibaudeau K; Bakis P; Bousquet-Gagnon N; Robitaille M; Bellomo M; Paradis V; Liscourt P; Lobach A; Rivard ME; Ptak RG; Mankowski MK; Bridon D; Quraishi O
J Biol Chem; 2008 Dec; 283(49):34045-52. PubMed ID: 18809675
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
Lu L; Tong P; Yu X; Pan C; Zou P; Chen YH; Jiang S
Biochim Biophys Acta; 2012 Dec; 1818(12):2950-7. PubMed ID: 22867851
[TBL] [Abstract][Full Text] [Related]
3. Preexposure prophylaxis with albumin-conjugated C34 peptide HIV-1 fusion inhibitor in SCID-hu Thy/Liv mice.
Stoddart CA; Nault G; Galkina SA; Bousquet-Gagnon N; Bridon D; Quraishi O
Antimicrob Agents Chemother; 2012 Apr; 56(4):2162-5. PubMed ID: 22252805
[TBL] [Abstract][Full Text] [Related]
4. Multimerized CHR-derived peptides as HIV-1 fusion inhibitors.
Nomura W; Hashimoto C; Suzuki T; Ohashi N; Fujino M; Murakami T; Yamamoto N; Tamamura H
Bioorg Med Chem; 2013 Aug; 21(15):4452-8. PubMed ID: 23800723
[TBL] [Abstract][Full Text] [Related]
5. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.
Liu S; Lu H; Niu J; Xu Y; Wu S; Jiang S
J Biol Chem; 2005 Mar; 280(12):11259-73. PubMed ID: 15640162
[TBL] [Abstract][Full Text] [Related]
6. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
[TBL] [Abstract][Full Text] [Related]
7. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.
Champagne K; Shishido A; Root MJ
J Biol Chem; 2009 Feb; 284(6):3619-27. PubMed ID: 19073602
[TBL] [Abstract][Full Text] [Related]
8. Conjugation of cholesterol to HIV-1 fusion inhibitor C34 increases peptide-membrane interactions potentiating its action.
Hollmann A; Matos PM; Augusto MT; Castanho MA; Santos NC
PLoS One; 2013; 8(4):e60302. PubMed ID: 23565220
[TBL] [Abstract][Full Text] [Related]
9. A synthetic C34 trimer of HIV-1 gp41 shows significant increase in inhibition potency.
Nomura W; Hashimoto C; Ohya A; Miyauchi K; Urano E; Tanaka T; Narumi T; Nakahara T; Komano JA; Yamamoto N; Tamamura H
ChemMedChem; 2012 Feb; 7(2):205-8. PubMed ID: 22247043
[No Abstract] [Full Text] [Related]
10. Identification of a human protein-derived HIV-1 fusion inhibitor targeting the gp41 fusion core structure.
Chao L; Lu L; Yang H; Zhu Y; Li Y; Wang Q; Yu X; Jiang S; Chen YH
PLoS One; 2013; 8(5):e66156. PubMed ID: 23741527
[TBL] [Abstract][Full Text] [Related]
11. Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus.
Leslie GJ; Wang J; Richardson MW; Haggarty BS; Hua KL; Duong J; Secreto AJ; Jordon AP; Romano J; Kumar KE; DeClercq JJ; Gregory PD; June CH; Root MJ; Riley JL; Holmes MC; Hoxie JA
PLoS Pathog; 2016 Nov; 12(11):e1005983. PubMed ID: 27855210
[TBL] [Abstract][Full Text] [Related]
12. Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy.
Zhu X; Zhu Y; Ye S; Wang Q; Xu W; Su S; Sun Z; Yu F; Liu Q; Wang C; Zhang T; Zhang Z; Zhang X; Xu J; Du L; Liu K; Lu L; Zhang R; Jiang S
Sci Rep; 2015 Aug; 5():13028. PubMed ID: 26286358
[TBL] [Abstract][Full Text] [Related]
13. Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide.
Nishikawa H; Nakamura S; Kodama E; Ito S; Kajiwara K; Izumi K; Sakagami Y; Oishi S; Ohkubo T; Kobayashi Y; Otaka A; Fujii N; Matsuoka M
Int J Biochem Cell Biol; 2009 Apr; 41(4):891-9. PubMed ID: 18834950
[TBL] [Abstract][Full Text] [Related]
14. Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.
Izumi K; Kodama E; Shimura K; Sakagami Y; Watanabe K; Ito S; Watabe T; Terakawa Y; Nishikawa H; Sarafianos SG; Kitaura K; Oishi S; Fujii N; Matsuoka M
J Biol Chem; 2009 Feb; 284(8):4914-20. PubMed ID: 19073606
[TBL] [Abstract][Full Text] [Related]
15. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
Gallo SA; Sackett K; Rawat SS; Shai Y; Blumenthal R
J Mol Biol; 2004 Jun; 340(1):9-14. PubMed ID: 15184018
[TBL] [Abstract][Full Text] [Related]
16. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
Gustchina E; Hummer G; Bewley CA; Clore GM
J Med Chem; 2005 Apr; 48(8):3036-44. PubMed ID: 15828842
[TBL] [Abstract][Full Text] [Related]
17. The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.
Zhu Y; Ding X; Yu D; Chong H; He Y
J Virol; 2019 Dec; 94(1):. PubMed ID: 31619552
[TBL] [Abstract][Full Text] [Related]
18. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
[TBL] [Abstract][Full Text] [Related]
19. Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor.
Chong H; Yao X; Zhang C; Cai L; Cui S; Wang Y; He Y
PLoS One; 2012; 7(3):e32599. PubMed ID: 22403678
[TBL] [Abstract][Full Text] [Related]
20. Suitable fusion of N-terminal heptad repeats to achieve covalently stabilized potent N-peptide inhibitors of HIV-1 infection.
Lai W; Wang C; Yan J; Liu H; Zhang W; Lin B; Xi Z
Bioorg Med Chem; 2020 Feb; 28(4):115214. PubMed ID: 31932193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]